New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. Gradishar

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Bagegni & Dr. GradisharПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Mahtani & Dr. SchwartzbergПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Kevin KalinskyПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Meisel & Dr. SolimanПодробнее

Optimizing HER2-Positive Breast Cancer Therapy: Balancing Efficacy and ToxicityПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Kaklamani and Dr. O’ReganПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Traina & Dr. CareyПодробнее

New & Supporting Data for Optimizing Therapy in HER2+ Breast Cancer | Dr. Irene and Dr. VogelПодробнее

Dr. Pegram on Neoadjuvant Treatments for HER2-Postive Breast CancerПодробнее

New Data on the Second Line Treatment of HER2+ Breast CancerПодробнее

Neo-PATH: TAHP for patients with HER2-positive breast cancerПодробнее

Science behind NFκB activation in HER2+ breast cancer & its link with inflammation & cancer #HER2Подробнее

Considerations for Pre-operative Therapy to Optimize Care of Women with HER2+ Breast CancerПодробнее

Predicting Breast Cancer in Women under 50 by using AI with Gabbi, Inc.Подробнее

HER2-Positive Biliary Tract Cancer: New Developments and Future DirectionsПодробнее

Treatment optimization trials in breast cancerПодробнее

Dr. O’Regan on Prognostic Value of pCR in HER2+ Breast CancerПодробнее

Dr. Shao on Prognosis of Patients With HER2+ Breast CancerПодробнее

Research into New Immunotherapies for Breast CancerПодробнее